Drugs / Synera
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | SYNERA | — | 2005-06-23 | fda.gov ↗ |
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01602757 | Feb → Mar 2010 | — | ZARS Pharma Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00991068 | Sep 2009 → Mar 2010 | carpal tunnel syndrome | ZARS Pharma Inc. | Completed | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT01834586 | Mar 2013 → Mar 2015 | multiple sclerosis | Brown, Theodore R., M.D., MPH | Completed | No outcome recorded |
| Phase 4 | NCT01525043 | Feb 2012 → Feb 2013 | epicondylitis | International Clinical Research Institute | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT01775605 Comparator | Nov 2013 → Nov 2014 | anxiety | Northwell Health | Withdrawn | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Synera | “ZARS Pharma, Inc. has developed Synera® (lidocaine 70 mg and tetracaine 70 mg topical patch), a drug delivery patch that utilizes controlled heat to enhance the delivery of a...” NCT00991068 ↗ |
| Known as | Synera patch | “Synera patch ®: A single patch applied for 4 hours twice daily approximatey 12 hrs apart to the medial or lateral side of the index elbow” NCT01525043 ↗ |
| Route | Topical | “Synera topical patch” NCT00991068 ↗ |